Applied Molecular Transport (AMTI) – Company Press Releases
-
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
-
Cyclo Therapeutics Reports Third Quarter 2023 Financial Results
-
Applied Molecular Transport Reports Third Quarter 2023 Financial Results
-
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement
-
Applied Molecular Transport Reports Second Quarter 2023 Financial Results
-
Applied Molecular Transport Reports First Quarter 2023 Financial Results
-
Applied Molecular Transport Announces Corporate Leadership Change and Process to Explore Strategic Alternatives
-
Applied Molecular Transport Announces Corporate Leadership Change and Process to Explore Strategic Alternatives
-
Applied Molecular Transport Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-
Applied Molecular Transport Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-
Applied Molecular Transport Presents Additional Data from Oral AMT-101 Phase 2 FILLMORE Trial in Chronic Pouchitis at ECCO ’23 Congress
-
Applied Molecular Transport Presents Additional Data from Oral AMT-101 Phase 2 FILLMORE Trial in Chronic Pouchitis at ECCO ’23 Congress
-
Applied Molecular Transport Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
-
Applied Molecular Transport Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
-
Applied Molecular Transport Announces FDA Orphan Drug Designation Granted to AMT-101 for Treatment of Pouchitis
-
Applied Molecular Transport Announces FDA Orphan Drug Designation Granted to AMT-101 for Treatment of Pouchitis
-
Applied Molecular Transport to Present at Upcoming November Investor Conferences
-
Applied Molecular Transport to Present at Upcoming November Investor Conferences
-
Applied Molecular Transport Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Applied Molecular Transport Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Applied Molecular Transport Completes Enrollment of Phase 2 LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
-
Applied Molecular Transport Completes Enrollment of Phase 2 LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
-
Applied Molecular Transport Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
Applied Molecular Transport Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
Applied Molecular Transport Announces Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
-
Applied Molecular Transport Announces Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
-
Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
-
Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
-
Applied Molecular Transport to Present at Upcoming June Investor Conferences
-
Applied Molecular Transport to Present at Upcoming June Investor Conferences
-
Applied Molecular Transport Provides Strategy Update
-
Applied Molecular Transport Provides Strategy Update
-
Applied Molecular Transport Reports First Quarter 2022 Financial Results and Provides Corporate Update
-
Applied Molecular Transport Reports First Quarter 2022 Financial Results and Provides Corporate Update
-
Applied Molecular Transport to Present at BofA Securities 2022 Healthcare Conference
-
Applied Molecular Transport to Present at BofA Securities 2022 Healthcare Conference
-
Applied Molecular Transport Announces Positive Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis
-
Applied Molecular Transport Announces Positive Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis
-
Applied Molecular Transport to Report Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis
-
Applied Molecular Transport to Report Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis
-
Applied Molecular Transport Announces Publication in Tissue Barriers Providing Additional Insight into Company’s Proprietary Technology Platform
-
Applied Molecular Transport Announces Publication in Tissue Barriers Providing Additional Insight into Company’s Proprietary Technology Platform
-
Applied Molecular Transport Appoints Charlene Banard to its Board of Directors
-
Applied Molecular Transport Appoints Charlene Banard to its Board of Directors
-
Applied Molecular Transport Appoints Industry Veteran Carolyn Finkle as Senior Vice President, Head of Regulatory Affairs
-
Applied Molecular Transport Appoints Industry Veteran Carolyn Finkle as Senior Vice President, Head of Regulatory Affairs
-
Applied Molecular Transport Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
-
Applied Molecular Transport Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
-
Applied Molecular Transport to Present at SVB Leerink Virtual 11th Annual Global Healthcare Conference
-
Applied Molecular Transport to Present at SVB Leerink Virtual 11th Annual Global Healthcare Conference
Back to AMTI Stock Lookup
